hs-cTnT、sST2联合BNP评估射血分数降低的慢性心力衰竭的临床意义

Abstract
Figure/Table
References
Related Citation (5)

Download: PDF (563 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the clinical significance and correlationship of high sensitivitytroponin T (hscTnT), soluble suppression of tumorigenicity 2 (sST2) and Btype natriuretic peptide (BNP) in chronic heart failure with reduced ejection fraction (HFrEF). Methods: Fiftynine patients with chronic heart failure whose left ventricular ejection fraction (LVEF) was less than 40% were enrolled in the study group.Thirty patients with no history of heart failure and heart disease were collected as control group during the same period. The serum levels of hscTnT, sST2 and their correlation with BNP were compared between the two groups, and the levels of hscTnT, sST2 and BNP were detected to correlate with cardiac function classification, rehospitalization rate and cardiovascular mortality rate. Results: The levels of hscTnT and sST2 were significantly higher than those in the control group (P<0.001), and both were positively correlated with BNP(r=0.783 and 0.794, both P<0.01),respectively. The hscTnT were negatively correlated with LVEF(Ⅱ:r＝-0.605,P<0.05;ⅢⅣ:r=-0.707,P<0.05). The sST2 were negatively correlated with LVEF(Ⅱ: r＝-0.607，P＜0.05; ⅢⅣ:r=-0.762,P<0.05), while BNP and LVEF were positively correlated（r＝0.505,P<0.05；r=0.497,P<0.05）. After six months of followup outside hospital, the incidence of rehospitalization and cardiovascular death was significantly higher in the hscTnT and sST2 highvalue groups than that in the lowvalue group (P<0.05). Conclusion: hscTnT, sST2 combined with BNP have a good predictive value for the severity of HFrEF patients and cardiovascular events.

Received: 02 July 2019

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2019/V29/I05/414

［1］黄峻. 中国心力衰竭流行病学特点和防治策略\[J\]. 中华心脏与心律电子杂志, 2015,3(2):81-82.
［2］胡盛寿，高润霖，刘力生，等.中国心血管病报告2018概要\[J\]. 中国循环杂志, 2019,34(3):209-220.
［3］Askoxylakis V, Thieke C, Pleger ST, et al. Longterm survival of cancer patients compared to heart failure and stroke: A systematic review\[J\]. BMC Cancer, 2010, 10:105.
［4］Ponikowski P, Anker SD, Alhabib KF, et al. Heart failure: preventing disease and death worldwide\[J\]. ESC Heart Fail, 2014，1(1) : 4-25.
［5］中华医学会心血管病学分会. 中国心力衰竭诊断和治疗指南2014\[J\]. 中华心血管病杂志, 2014, 42(2):3-10.
［6］Braunwald E. Heart Failure\[J\]. JACC Heart Fail, 2013, 1(1):1-20.
［7］Evans JDW, Dobbin SJH, Pettit SJ, et al. Highsensitivity cardiac troponin and newonset heart failure: a systematic review and metaanalysis of 67,063 patients with 4,165 incident heart failure events\[J\]. JACC Heart Fail, 2018， 6(3): 187-197.
［8］De Boer RA, Nayor M, DeFilippi CR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction\[J\]. JAMA Cardiol, 2018, 3(3): 215-224.
［9］Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America\[J\]. J Am Coll Cardiol, 2017, 70(6): 776-803.
［10］罗玲, 马爱群. 2017版ACC／AHA／HFSA心力衰竭管理指南更新的解读\[J\]. 中华医学信息导报, 2017, 32(13):18.
［11］Fonarow GC. Biomarkerguided vs guidelinedirected titration of medical therapy for heart failure\[J\]. JAMA, 2017, 318(8): 707-708.
［12］St Peter JV, Hartley GG, Murakami MM， et al.Btype natriuretic peptide (BNP) and Nterminal proBNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery\[J\]. Clin Chem, 2006, 52(4):680-685.
［13］Latini R , Masson S . Significance of measurable cardiac troponin by highsensitivity assays in patients with chronic stable heart failure\[J\]. Coron Artery Dis, 2013, 24(8):716-719.
［14］Okura H，Suzuki R，Azuma Y，et al.The basic research on the highsensitive troponin I assay，and the application to evaluation of chronic heart failure\[J\]. Rinsho Byori,2013,61(5): 375-381.
［15］AlquézarArbé A, Sionis A, OrdoezLlanos J. Cardiac troponins: 25 years on the stage and still improving their clinical value\[J\]. Crit Rev Clin Lab Sci, 2017，54(7-8):551-571.
［16］Seliger S, HongZohlman S, deLemos J, et al. High sensitive cardiac troponin T predicts longterm risk of incident HF independent of cardiovascular risk factors and cardiac structure/function in a multiethnic population without CVD: the multiethnic study of atherosclerosis\[J\]. Circulation, 2016, 134(suppl 1): A16572.
［17］McEvoy JW, Chen Y, Ndumele CE, et al. Sixyear change in highsensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death\[J\]. JAMA Cardiol, 2016, 1(5): 519-528.
［18］Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker\[J\]. Circulation, 2003, 107(5): 721-726.
［19］Ky B, French B, McCloskey K, et al. Highsensitivity ST2 for prediction of adverse outcomes in chronic heart failure\[J\]. Circ Heart Fail, 2011, 4(2): 180-187.
［20］ManzanoFernandez S, Januzzi JL, PastorPerez FJ, et al. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure\[J\]. Cardiology, 2012, 122(3): 158-166.